000089812 001__ 89812
000089812 005__ 20210902121807.0
000089812 0247_ $$2doi$$a10.1177/1758835920920067
000089812 0248_ $$2sideral$$a118286
000089812 037__ $$aART-2020-118286
000089812 041__ $$aeng
000089812 100__ $$aPuente, J.
000089812 245__ $$aExpert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
000089812 260__ $$c2020
000089812 5060_ $$aAccess copy available to the general public$$fUnrestricted
000089812 5203_ $$aObjective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT.
Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted ¿7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations.
Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.
000089812 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000089812 590__ $$a8.168$$b2020
000089812 591__ $$aONCOLOGY$$b36 / 242 = 0.149$$c2020$$dQ1$$eT1
000089812 592__ $$a2.271$$b2020
000089812 593__ $$aOncology$$c2020$$dQ1
000089812 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000089812 700__ $$aAnido, U.
000089812 700__ $$aCliment, M.Á.
000089812 700__ $$aGonzalez-Billalabeitia, E.
000089812 700__ $$aLainez, N.
000089812 700__ $$0(orcid)0000-0003-0063-1067$$aLambea, J.$$uUniversidad de Zaragoza
000089812 700__ $$aMaroto, J.P.
000089812 700__ $$aMendez-Vidal, M.J.
000089812 700__ $$aMontesa, Á.
000089812 700__ $$aRodriguez, A.
000089812 700__ $$aZambrana, C.
000089812 700__ $$aGonzález-del-Alba, A.
000089812 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000089812 773__ $$g12 (2020), 1-12$$pTher. adv. med. oncol.$$tTherapeutic Advances in Medical Oncology$$x1758-8340
000089812 8564_ $$s148085$$uhttps://zaguan.unizar.es/record/89812/files/texto_completo.pdf$$yVersión publicada
000089812 8564_ $$s30681$$uhttps://zaguan.unizar.es/record/89812/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000089812 909CO $$ooai:zaguan.unizar.es:89812$$particulos$$pdriver
000089812 951__ $$a2021-09-02-09:58:45
000089812 980__ $$aARTICLE